Serum lactate dehydrogenase and CD4+/CD8+ lymphocyte ratio predict survival in terminally ill cancer patients

Takeshi Ohara, Masahiko Takahashi, Hiroyuki Yamanaka, Yoko Yamamoto, Akira Shimada, Toshimichi Nakaho

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Accurate estimation of survival is important for effective palliative medicine of patients with cancer. In most clinical practice, however, the life expectancy has been predicted based on subjective evaluations. The purpose of this study was to find objective biological markers that can contribute to accurate prediction of survival in terminally ill cancer patients. Consecutive terminally ill cancer patients admitted to the Palliative Care Center in Tohoku University hospital from January to May 2001 were approached for this study. Forty-eight blood samples were obtained from 25 patients who provided a written informed consent. Common serum enzyme markers were determined using standard hospital laboratory methods. Cellular immunity status was evaluated by peripheral blood lymphocyte-subset analysis using flow cytometry. Mean patient survival was 33.5 +/- 21.6 (1-80) days. Multiple regression analysis revealed that lactate dehydrogenase (LDH) and the CD4+/CD8+ ratio were significantly associated with survival (r = 0.64, p < 0.0001). Further prospective studies are warranted to validate the usefulness of these determinants for accurate prediction of survival.

Original languageEnglish
Pages (from-to)1779-1783
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume29
Issue number10
Publication statusPublished - 2002 Oct

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serum lactate dehydrogenase and CD4+/CD8+ lymphocyte ratio predict survival in terminally ill cancer patients'. Together they form a unique fingerprint.

Cite this